aurobindo pharma (Emkay) Growth intact, maintain BUY

US business and ARV formulations portfolio drive Q4FY11 performance; Growth will continue going forward due to multiple growth drivers
Date Rating Target Price Recommendation Price Broker house
9 May 2011 buy 265 182 Emkay Report

No comments:

Post a Comment